Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis
Status:
Recruiting
Trial end date:
2022-09-13
Target enrollment:
Participant gender:
Summary
This is a parallel, treatment, Phase 2, double-blind, 2-arm study in adult participants (aged
at least 18 years) with moderate-to-severe atopic dermatitis (AD) and intolerance or
inadequate response to topical corticosteroids (TCS).
The total study duration per participant is expected to be approximately 21 weeks, including:
Screening: up to 4 weeks On-treatment double-blind period: 16 weeks Post-treatment follow-up:
1 week